S&P Futures
3,771.75 -49.50 (-1.30%) Dow Futures
30,652.00 -347.00 (-1.12%) Nasdaq Futures
11,515.25 -175.75 (-1.50%) Russell 2000 Futures
1,695.20 -26.20 (-1.52%) Crude Oil
109.23 -0.55 (-0.50%) Gold
1,810.70 -6.80 (-0.37%)
Salarius Pharmaceuticals, Inc. (SLRX)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 0.2009 |
| Open | 0.1951 |
| Bid | 0.2051 x 2900 |
| Ask | 0.2299 x 1300 |
| Day's Range | 0.1951 - 0.2385 |
| 52 Week Range | 0.1600 - 1.2000 |
| Volume | |
| Avg. Volume | 1,159,398 |
| Market Cap | 9.823M |
| Beta (5Y Monthly) | 1.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3070 |
| Earnings Date | Mar 16, 2022 - Mar 21, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.25 |
- GlobeNewswire
Salarius Pharmaceuticals to Participate in BIO International Convention 2022
HOUSTON, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will participate in the 2022 BIO International Convention in San Diego from June 13-16, 2022. During the conference, attended by over 15,000 industry leaders, members of the Salarius team will provide updates on its two drug candidates, the Targeted Pro
- GlobeNewswire
Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other solid and hematological cancers, today announced that David Arthur, CEO of Salarius Pharmaceuticals, will be virtually presenting at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022. The presentation will provide an overview of recent business an
- GlobeNewswire
Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results
Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA Advancing multiple drug development programs, led by SP-3164 in targeted protein degradation, and seclidemstat in protein inhibition, a clinical-stage reversible LSD1 inhibitor Multiple potential development and data milestones expected from both programs in 2H 2022 2022 Annual Meeting of Stockholders announced for June 15, 2022; Company is encouraging all stockholders to participate and vote their shares of Salarius Pharma
